Immuno-Biological Laboratories Co (TSE:4570) ROCE % : 0.00% (As of Sep. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Immuno-Biological Laboratories Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Immuno-Biological Laboratories Co's annualized ROCE % for the quarter that ended in Sep. 2024 was 0.00%.

Immuno-Biological Laboratories Co ROCE % Historical Data

The historical data trend for Immuno-Biological Laboratories Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immuno-Biological Laboratories Co ROCE % Chart

Immuno-Biological Laboratories Co Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

ROCE %

Get a 7-Day Free Trial

-29.81

-16.90

-15.74

-21.02

9.89

Immuno-Biological Laboratories Co Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Sep24
ROCE %	Get a 7-Day Free Trial															4.38	5.78	-1.51	31.24	-

Immuno-Biological Laboratories Co ROCE % Calculation

Immuno-Biological Laboratories Co's annualized ROCE % for the fiscal year that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2024 )		(A: Mar. 2023 )		(A: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2024 )		(A: Mar. 2023 )		(A: Mar. 2024 )
	=	125.774	/	( ( (1434.337 - 252.005)	+	(1618.582 - 257.824) )	/ 2 )
	=	125.774	/	( (1182.332	+	1360.758)	/ 2 )
	=	125.774	/	1271.545
	=	9.89 %

Immuno-Biological Laboratories Co's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Mar. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Mar. 2024 )		(Q: Sep. 2024 )
	=	0	/	( ( (1618.582 - 257.824)	+	(1645.596 - 262.302) )	/ 2 )
	=	0	/	( ( 1360.758	+	1383.294 )	/ 2 )
	=	0	/	1372.026
	=	0.00 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

Immuno-Biological Laboratories Co (TSE:4570) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Immuno-Biological Laboratories Co ROCE % Related Terms

Thank you for viewing the detailed overview of Immuno-Biological Laboratories Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Immuno-Biological Laboratories Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immuno-Biological Laboratories Co Ltd (TSE:4570) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

1091-1 Naka Aza-Higashida, Gunma, Fujioka, JPN, 375-0005

Website

http://www.ibl-japan.co.jp

Immuno-Biological Laboratories Co Ltd focuses on research and development. It researches, develops, manufacture and supplies various immunological research reagents, and customized services. It is engaged in research and development of materials used in diagnostic products and valuable seeds and technology for protein production using transgenic silkworm cocoons, which make it possible to create valuable proteins as well as antibodies. It works on clinical reagents for cancer research. Its research scientists are producing inflammatory cytokines, growth factors & antibodies for use against these cancers.

Immuno-Biological Laboratories Co Headlines

No Headlines